Excellence in monoclonal antibody and immunoassay development

Focus on...

Discover Diaclone

With over 30 years of experience and expertise, high quality has become the hallmark of the Diaclone Immunology products, firmly establishing us as a centre of excellence in Monoclonal Antibody research and Immunoassay Kit development.

Our experience and expertise coupled to the diversity and quality of our product range makes Diaclone a clear choice to Fast Track Your Research.

The expanding range of Diaclone immunology products is specifically designed for key research in clinical and preclinical applications by the pharmaceutical industry, biotechnology and diagnostic companies but also by public research laboratories in France and internationally.

Product types

Monoclonal Antibodies: unconjugated, labelled or azide free formats.

Immunoassays ELISA and ELISpot: pair, set and kit formats, ELISpot mono or dual

Recombinant proteins: Human Interleukins, SARS-CoV-2 and other targets under development

Standard catalogue and bulk sizes on request

The major research fields

Immunotherapy & Cancer - Vaccinology - Inflammation - Allergy - Autoimmune diseases - Apoptosis ...

The main applications

CD markers, Cytokine and Growth factors, TRAIL receptors, Cell adhesion molecules (CAM), In vivo controls, T-Cells…

A large range of specificities

Interleukins e.g. IL-2, IL-6, IL-8, IL-17 family…, CD markers e.g. CD138 (Syndecan), CD126…, IFN gamma, TNF alpha, Perforin, Granzyme, Isotype controls…

Target species: human, murine, rat, porcine…

The Diaclone service

Products developed in our own  laboratories by experts in immunology, for a high-quality service, deliveries within 48 hours, and direct  technical and scientific assistance.

Diaclone is based in Besançon, France, and is a part of Medix Biochemica Group, a leading global supplier of critical raw materials to the in vitro diagnostics (IVD) industry.


Virostat Logo

Medix Biochemica Acquires ViroStat

Publication date : 2023-11-10
Medix Biochemica expands its infectious diseases antibody offering through the acquisition of ViroStat.

More info...